BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,237,668 | +17.2% | 2,010,970 | +16.6% | 0.00% | 0.0% |
| Q2 2023 | $12,143,725 | -8.2% | 1,724,961 | +8.7% | 0.00% | 0.0% |
| Q1 2023 | $13,231,994 | +21.8% | 1,586,570 | +67.6% | 0.00% | 0.0% |
| Q4 2022 | $10,866,038 | -52.0% | 946,519 | -47.3% | 0.00% | -50.0% |
| Q3 2022 | $22,630,000 | +76.0% | 1,796,015 | +47.7% | 0.01% | +100.0% |
| Q2 2022 | $12,861,000 | -40.9% | 1,215,661 | -9.1% | 0.00% | -40.0% |
| Q1 2022 | $21,747,000 | -4.3% | 1,337,456 | -18.5% | 0.01% | +25.0% |
| Q4 2021 | $22,721,000 | -38.4% | 1,640,473 | -36.1% | 0.00% | -50.0% |
| Q3 2021 | $36,889,000 | +5.8% | 2,567,054 | +16.4% | 0.01% | 0.0% |
| Q2 2021 | $34,872,000 | +78.6% | 2,205,703 | +14.9% | 0.01% | +60.0% |
| Q1 2021 | $19,520,000 | -62.9% | 1,919,412 | -72.8% | 0.01% | -64.3% |
| Q4 2020 | $52,644,000 | +68.4% | 7,066,317 | -22.4% | 0.01% | +75.0% |
| Q3 2020 | $31,261,000 | -26.6% | 9,100,731 | +1.9% | 0.01% | -42.9% |
| Q2 2020 | $42,565,000 | +241.9% | 8,932,808 | +43.5% | 0.01% | +180.0% |
| Q1 2020 | $12,451,000 | -39.6% | 6,225,434 | +4.1% | 0.01% | -44.4% |
| Q4 2019 | $20,630,000 | +87.3% | 5,979,879 | +55.5% | 0.01% | +80.0% |
| Q3 2019 | $11,017,000 | -19.3% | 3,845,171 | +6.8% | 0.01% | -16.7% |
| Q2 2019 | $13,651,000 | -25.2% | 3,601,898 | +60.7% | 0.01% | -33.3% |
| Q1 2019 | $18,239,000 | +213.8% | 2,240,775 | +211.1% | 0.01% | +200.0% |
| Q4 2018 | $5,812,000 | +1300.5% | 720,204 | +1226.7% | 0.00% | – |
| Q3 2018 | $415,000 | +8.6% | 54,287 | -18.6% | 0.00% | – |
| Q2 2018 | $382,000 | -82.7% | 66,689 | -85.6% | 0.00% | -100.0% |
| Q1 2018 | $2,204,000 | +1204.1% | 462,079 | +1235.5% | 0.00% | – |
| Q4 2017 | $169,000 | -97.8% | 34,600 | -97.6% | 0.00% | -100.0% |
| Q3 2017 | $7,585,000 | +664.6% | 1,447,547 | +711.1% | 0.01% | +500.0% |
| Q2 2017 | $992,000 | -35.4% | 178,458 | -2.4% | 0.00% | 0.0% |
| Q1 2017 | $1,536,000 | +57.4% | 182,825 | +18.5% | 0.00% | 0.0% |
| Q4 2016 | $976,000 | +308.4% | 154,254 | +185.1% | 0.00% | – |
| Q3 2016 | $239,000 | -85.4% | 54,100 | -62.4% | 0.00% | -100.0% |
| Q3 2015 | $1,641,000 | -86.2% | 143,954 | -81.9% | 0.00% | -80.0% |
| Q2 2015 | $11,863,000 | +3409.8% | 794,591 | +2025.5% | 0.01% | – |
| Q1 2015 | $338,000 | -63.0% | 37,384 | -60.0% | 0.00% | -100.0% |
| Q3 2014 | $914,000 | -25.3% | 93,409 | -2.8% | 0.00% | 0.0% |
| Q2 2014 | $1,224,000 | +973.7% | 96,068 | +787.8% | 0.00% | – |
| Q1 2014 | $114,000 | -64.9% | 10,821 | -74.7% | 0.00% | – |
| Q4 2013 | $325,000 | +606.5% | 42,803 | +42.8% | 0.00% | – |
| Q2 2013 | $46,000 | – | 29,974 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |